NCT02888743 2026-03-19
Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
8 trialsNCT06680739 2024-11-08
SERPENTINE
Vall d'Hebron Institute of Oncology
Phase 2 Recruiting
NCT00378482 2024-08-22
A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.
AstraZeneca
Phase 2 Completed
NCT02870920 2023-12-08
Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT03982173 2023-01-26
MATILDA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Withdrawn
NCT03122509 2022-07-06
A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03101475 2022-05-31
ILOC
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00313794 2012-06-07
Study of Ticilimumab in Patients With Metastatic Colorectal Cancer Whose Disease Had Progressed After Treatment
AstraZeneca
Phase 2 Completed